Form 4: Whitehawk Therapeutics CEO Sells Shares
Statement of Changes in Beneficial Ownership
Whitehawk Therapeutics CEO David James Lennon reported transactions involving the sale of company stock to cover tax obligations related to vested restricted stock units.
Summary
- David James Lennon, CEO of Whitehawk Therapeutics, Inc., reported the sale of company common stock on April 6th, 7th, and 8th, 2026.
- These sales totaled 260,427 shares.
- The sales were conducted to satisfy tax withholding obligations upon the vesting of restricted stock units.
- Lennon retains beneficial ownership of 533,122 shares of common stock following these transactions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as the reported stock sales are for tax withholding purposes related to vested equity, a common and expected event for executives.
Positives
- The CEO's transactions were to cover tax obligations, indicating a standard procedure for vested equity.
- David James Lennon continues to hold a significant number of shares (533,122) after the sales, suggesting continued confidence in the company.
Negatives
- A total of 260,427 shares were sold by the CEO, which could be perceived negatively by the market if not understood in context.
Risks
- Potential for negative market perception of insider selling, even if for tax purposes.
- The company's stock price may be affected by the volume of shares sold by a key executive.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to insider transactions.
Management Comments
- The sales were made to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures for public company executives and directors. Sales for tax withholding purposes are common and generally not indicative of a negative view on the company's prospects, provided the executive retains a substantial ownership stake.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO might cause short-term concern, but the explanation for the sale (tax withholding) mitigates this. The continued substantial ownership by the CEO is a positive signal.
Key Dates
| Date | Description |
|---|---|
| 04/06/2026 | Earliest transaction date reported for stock sales. |
| 04/07/2026 | Second transaction date reported for stock sales. |
| 04/08/2026 | Third transaction date reported for stock sales and signature date. |
Keywords
Form 4, Insider Trading, Stock Sale, Executive Compensation, Whitehawk Therapeutics, David James Lennon, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.